Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.33 | N/A | +3.26% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.33 | N/A | +3.26% |
| Revenue | N/A | N/A | N/A |
Tone: Confident
Overall, management conveyed confidence in the company's current trajectory. They noted strong performance in key areas, although no specific revenue guidance was provided.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing strength in their product portfolio.
AbbVie's earnings report shows that the company performed well on EPS, exceeding expectations. The positive stock reaction of 4.56% suggests that investors are pleased with the results, particularly in light of the strong EPS performance. However, the lack of revenue figures and guidance may leave some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ALPHABET INC Class C
Oct 26, 2021